Andreas Busch Ph.D.
Net Worth
Last updated:
What is Andreas Busch Ph.D. net worth?
The estimated net worth of Dr. Andreas Busch Ph.D. is at least $4,580,716 as of 9 Nov 2020. He owns shares worth $606,196 as insider and has received compensation worth at least $3,974,520 in Cyclerion Therapeutics, Inc..
What is the salary of Andreas Busch Ph.D.?
Dr. Andreas Busch Ph.D. salary is $662,420 per year as Chief Scientific Officer in Cyclerion Therapeutics, Inc..
How old is Andreas Busch Ph.D.?
Dr. Andreas Busch Ph.D. is 62 years old, born in 1963.
What stocks does Andreas Busch Ph.D. currently own?
As insider, Dr. Andreas Busch Ph.D. owns shares in one company:
| Company | Title | Shares | Price per share | Total value |
|---|---|---|---|---|
| Cyclerion Therapeutics, Inc. (CYCN) | Chief Scientific Officer | 254,704 | $2.38 | $606,196 |
What does Cyclerion Therapeutics, Inc. do?
Cyclerion Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovering, development, and commercialization of medicines for serious central nervous system (CNS) diseases. Its lead product candidate is CY6463, a CNS-penetrant, soluble guanylate cyclase (sGC) stimulator that is in Phase IIa trials for the treatment of mitochondrial encephalomyopathy, lactic acidosis, and stroke-like episodes, as well as Alzheimer's disease with vascular pathology; and Phase 1 trials diagnosed with schizophrenia in adults. It is also developing Praliciguat, an orally administered systemic sGC stimulator, which is in Phase II studies to treat resistant hypertension and diabetic nephropathy; Olinciguat, an orally administered vascular sGC stimulator that is in Phase II studies for the sickle cell disease; and CY3018 for the treatment of disorders of the CNS. It has license agreement with Akebia Therapeutics, Inc. for the development, manufacture, medical affairs, and commercialization of pharmaceutical products, including pharmaceutical compound, and other related products and forms. The company was incorporated in 2018 and is headquartered in Cambridge, Massachusetts.
Andreas Busch Ph.D. insider trading
Cyclerion Therapeutics key executives
Cyclerion Therapeutics, Inc. executives and other stock owners filed with the SEC:
- Dr. Andreas Busch Ph.D. (62) Chief Scientific Officer
- Dr. Peter M. Hecht Ph.D. (61) Chief Executive Officer, Interim Chief Financial Officer, Principal Accounting Officer & Director